In vitro efficacy of tyrosine kinase inhibitors: SYK and BCR-ABL inhibitors in lymphomas

Hematol Oncol. 2011 Sep;29(3):164-6. doi: 10.1002/hon.981. Epub 2011 Mar 17.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cell Line, Tumor
  • Fusion Proteins, bcr-abl / antagonists & inhibitors*
  • Humans
  • Intracellular Signaling Peptides and Proteins / antagonists & inhibitors*
  • Lymphoma, Large B-Cell, Diffuse / drug therapy*
  • Lymphoma, Large B-Cell, Diffuse / enzymology
  • Lymphoma, Large B-Cell, Diffuse / genetics
  • Protein Kinase Inhibitors / pharmacology*
  • Protein-Tyrosine Kinases / antagonists & inhibitors*
  • Syk Kinase

Substances

  • Intracellular Signaling Peptides and Proteins
  • Protein Kinase Inhibitors
  • Protein-Tyrosine Kinases
  • Fusion Proteins, bcr-abl
  • SYK protein, human
  • Syk Kinase